Mostrar el registro sencillo del ítem
dc.contributor.author | Bolanõs-Diáz, R. | |
dc.contributor.author | Angles-Yanqui, E. | |
dc.contributor.author | Perez-Lazo, G. | |
dc.contributor.author | Sanabria-Montañez, C. | |
dc.date.accessioned | 2022-06-01T13:53:57Z | |
dc.date.available | 2022-06-01T13:53:57Z | |
dc.date.issued | 2022 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/11744 | |
dc.description.abstract | Objectives: The objective of this study was to analyse the cost-effectiveness (C-E) of ceftazidime/avibactam (CAZ/AVI)-based therapy versus colistin (COL)-based therapy for pneumonia and bacteraemia caused by carbapenem-resistant enterobacteria (CRE) adjusted to Peruvian context. Methods: A Markov decision model was extrapolated from literature to evaluate the clinical and economic consequences of CAZ/AVI-based therapy compared to COL-based therapy for a hypothetical cohort of patients with CRE pneumonia or bacteraemia according to Peruvian context. It was adopted a 5-year time horizon and a Markov-cycle length of 1 year. All patients in the model were assigned to CRE pneumonia or bacteraemia state and may transit through four different health states: Home-care, long-term care without dialysis, long-term care with dialysis or death. Key findings: Intervention with CAZ/AVI becomes progressively more cost-effective from a threshold of S/24,000 or US$ 6666 (equivalent to 1 Gross Domestic Product-per cápita [GDP-pc]). The model simulation allowed to calculate an average total cost of S/2'971,582 (US$ 825,440) for CAZ/AVI against S/2'056,488 (US$ 571.247) for COL treatment, yielding an incremental cost of S/915,094 (US$ 254,193). The cost/QALY for CAZ/AVI treatment against COL therapy approaches to S/23,154 (US$ 6432), something less than 1 annual GDP-pc. There were additional benefits associated with CAZ/AVI in the 5-year horizon, such as: 21 deaths avoided, 86 hospital days avoided, 1 CRF5 avoided and a NMB of S/6649 (US$ 1847). Conclusions: The present transferability model demonstrates the C-E of CAZ/AVI over COL for the treatment of bacteraemia and CRE pneumonia according to peruvian payment thresholds. | en_US |
dc.language.iso | eng | |
dc.publisher | Oxford University Press | |
dc.relation.ispartofseries | Journal of Pharmaceutical Health Services Research | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Cost-effectiveness | en_US |
dc.subject | Ceftazidime/avibactam | en_US |
dc.subject | Colistin | en_US |
dc.subject | Pneumonia | en_US |
dc.subject | Bacteraemia | en_US |
dc.title | Cost-effectiveness of ceftazidime/avibactam for infections due to carbapenem-resistant bacteria in Peru | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1093/jphsr/rmab015 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.01.05 | |
dc.relation.issn | 1759-8885 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |